Verve Net Debt from 2010 to 2025

VERV Stock

USD 7.41 0.29 3.77%

Verve Therapeutics Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt is likely to outpace its year average in 2025. Net Debt is the total debt of Verve Therapeutics minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2010-12-31

Previous Quarter

-118.1 M

Current Value

-112.2 M

Quarterly Volatility

69.5 M

Credit Downgrade

Yuan Drop

Covid

Check Verve Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verve Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 25.8 M, Interest Income of 8.3 M or Depreciation And Amortization of 3.3 M, as well as many indicators such as Price To Sales Ratio of 83.12, Dividend Yield of 0.0 or PTB Ratio of 1.41. Verve financial statements analysis is a perfect complement when working with Verve Therapeutics Valuation or Volatility modules.

Check out the analysis of Verve Therapeutics Correlation against competitors.

For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.

Latest Verve Therapeutics' Net Debt Growth Pattern

Below is the plot of the Net Debt of Verve Therapeutics over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Verve Therapeutics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Verve Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Verve Net Debt Regression Statistics

	Arithmetic Mean	(1,294,320)
	Coefficient Of Variation	(5,373)
	Mean Deviation	56,381,815
	Median	32,065,000
	Standard Deviation	69,546,420
	Sample Variance	4836.7T
	Range	247.4M
	R-Value	(0.68)
	Mean Square Error	2793T
	R-Squared	0.46
	Significance	0
	Slope	(9,918,543)
	Total Sum of Squares	72550.6T

Verve Net Debt History

	2025	-112.2 M
	2024	-118.1 M
	2023	-131.3 M
	2022	-33.5 M
	2021	-62.4 M
	2020	116.2 M

Other Fundumenentals of Verve Therapeutics

Net Debt To E B I T D A

Verve Therapeutics Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Net Receivables	Capital Surpluse	Deferred Long Term Liab
Total Assets		1.0	0.99	0.89	-0.91	-0.98	0.7	0.94	0.78	1.0	1.0	1.0	1.0	0.82	1.0	0.99	0.56	0.92	-0.69
Total Stockholder Equity	1.0		1.0	0.86	-0.93	-0.97	0.74	0.95	0.72	1.0	1.0	1.0	1.0	0.82	1.0	0.98	0.54	0.91	-0.67
Net Tangible Assets	0.99	1.0		0.84	-0.93	-0.97	0.74	0.95	0.71	1.0	0.99	0.99	0.99	0.84	0.99	0.98	0.51	0.9	-0.65
Current Deferred Revenue	0.89	0.86	0.84		-0.81	-0.91	0.56	0.74	0.8	0.86	0.88	0.89	0.88	0.63	0.89	0.92	0.71	0.89	-0.77
Net Debt	-0.91	-0.93	-0.93	-0.81		0.91	-0.89	-0.85	-0.53	-0.93	-0.91	-0.93	-0.91	-0.66	-0.93	-0.87	-0.65	-0.81	0.6
Retained Earnings	-0.98	-0.97	-0.97	-0.91	0.91		-0.72	-0.94	-0.82	-0.97	-0.98	-0.98	-0.98	-0.79	-0.98	-0.98	-0.65	-0.93	0.61
Accounts Payable	0.7	0.74	0.74	0.56	-0.89	-0.72		0.75	0.37	0.74	0.72	0.76	0.72	0.42	0.76	0.63	0.73	0.63	-0.36
Short Term Investments	0.94	0.95	0.95	0.74	-0.85	-0.94	0.75		0.77	0.95	0.94	0.93	0.94	0.88	0.93	0.92	0.53	0.92	-0.43
Total Liab	0.78	0.72	0.71	0.8	-0.53	-0.82	0.37	0.77		0.72	0.77	0.74	0.77	0.69	0.74	0.81	0.6	0.86	-0.43
Net Invested Capital	1.0	1.0	1.0	0.86	-0.93	-0.97	0.74	0.95	0.72		1.0	1.0	1.0	0.82	1.0	0.98	0.54	0.91	-0.67
Total Current Assets	1.0	1.0	0.99	0.88	-0.91	-0.98	0.72	0.94	0.77	1.0		1.0	1.0	0.81	1.0	0.99	0.56	0.91	-0.69
Capital Stock	1.0	1.0	0.99	0.89	-0.93	-0.98	0.76	0.93	0.74	1.0	1.0		1.0	0.77	1.0	0.98	0.6	0.9	-0.7
Net Working Capital	1.0	1.0	0.99	0.88	-0.91	-0.98	0.72	0.94	0.77	1.0	1.0	1.0		0.81	1.0	0.99	0.56	0.91	-0.69
Short Term Debt	0.82	0.82	0.84	0.63	-0.66	-0.79	0.42	0.88	0.69	0.82	0.81	0.77	0.81		0.77	0.85	0.17	0.86	-0.32
Common Stock	1.0	1.0	0.99	0.89	-0.93	-0.98	0.76	0.93	0.74	1.0	1.0	1.0	1.0	0.77		0.98	0.6	0.9	-0.7
Property Plant Equipment	0.99	0.98	0.98	0.92	-0.87	-0.98	0.63	0.92	0.81	0.98	0.99	0.98	0.99	0.85	0.98		0.54	0.94	-0.69
Net Receivables	0.56	0.54	0.51	0.71	-0.65	-0.65	0.73	0.53	0.6	0.54	0.56	0.6	0.56	0.17	0.6	0.54		0.63	-0.41
Capital Surpluse	0.92	0.91	0.9	0.89	-0.81	-0.93	0.63	0.92	0.86	0.91	0.91	0.9	0.91	0.86	0.9	0.94	0.63		-0.52
Deferred Long Term Liab	-0.69	-0.67	-0.65	-0.77	0.6	0.61	-0.36	-0.43	-0.43	-0.67	-0.69	-0.7	-0.69	-0.32	-0.7	-0.69	-0.41	-0.52

Click cells to compare fundamentals

About Verve Therapeutics Financial Statements

Verve Therapeutics investors use historical fundamental indicators, such as Verve Therapeutics' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Verve Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-118.1 M	-112.2 M
Net Debt To EBITDA	0.54	0.57

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Verve Net Debt from 2010 to 2025

Latest Verve Therapeutics' Net Debt Growth Pattern

Verve Net Debt Regression Statistics

Verve Net Debt History

Other Fundumenentals of Verve Therapeutics

Verve Therapeutics Net Debt component correlations

About Verve Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Verve Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY